Better Buy: Johnson & Johnson vs. Pfizer
They're two of the oldest, largest, and most respected healthcare companies around. But one has made investors much happier than the other in recent years. Johnson & Johnson (NYSE: JNJ) stock is up more than twice as much as Pfizer (NYSE: PFE) stock over the past five years, and it's a similar story so far in 2017.
That's looking in the rearview mirror, though. Which of these healthcare stocks is the better choice for long-term investors now? Here's how Johnson & Johnson and Pfizer compare.
Source: Fool.com
Johnson & Johnson Stock
The stock is one of the favorites of our community with 33 Buy predictions and 1 Sell predictions.
With a target price of 195 € there is a positive potential of 42.59% for Johnson & Johnson compared to the current price of 136.76 €.